Abstract
Cholangiocarcinoma (CCA) is the most common malignancy in patients with primary sclerosing cholangitis (PSC) and carries a high rate of mortality. Although the pathogenesis of CCA in PSC is largely unknown, inflammation-driven carcinogenesis concomitant with various genetic and epigenetic abnormalities are underlying factors. The majority of CCA cases develop from a dominant stricture (DS), which is defined as a stricture with a diameter < 1.5 mm in the common bile duct or < 1.0 mm in the hepatic duct. In PSC patients presenting with an abrupt aggravation of jaundice, pain, fatigue, pruritus, weight loss, or worsening liver biochemistries, CCA should be suspected and evaluated utilizing a variety of diagnostic modalities. However, early recognition of CCA in PSC remains a major challenge. Importantly, 30–50% of CCA in PSC patients are observed within the first year following the diagnosis of PSC followed by an annual incidence ranging from 0.5 to 1.5 per 100 persons, which is nearly 10 to 1000 times higher than that in the general population. Cumulative 5-year, 10-year, and lifetime incidences are 7%, 8–11%, and 9–20%, respectively. When PSC-associated CCA is diagnosed, most tumors are unresectable, and no effective medications are available. Given the poor therapeutic outcome, the surveillance and management of PSC patients who are at an increased risk of developing CCA are of importance. Such patients include older males with large-duct PSC and possibly concurrent ulcerative colitis. Thus, more attention should be paid to patients with these clinical features, in particular within the first year after PSC diagnosis. In contrast, CCA is less frequently observed in pediatric or female PSC patients or in those with small-duct PSC or concurrent Crohn’s disease. Recently, new biomarkers such as antibodies to glycoprotein 2 have been found to be associated with an increased risk of developing CCA in PSC. Herein, we review the literature on the pathogenesis, incidence, clinical features, and risk factors, with a focus on various diagnostic modalities of PSC-associated CCA.
Similar content being viewed by others
Abbreviations
- CA 19-9:
-
Carbohydrate antigen 19-9
- CCA:
-
Cholangiocarcinoma
- CEA:
-
Carcinoembryonic antigen
- CLM:
-
Confocal laser microscopy
- COX-2:
-
Cyclooxygenase-2
- CT:
-
Computed tomography
- DS:
-
Dominant stricture
- EGFR:
-
Epidermal growth factor receptor
- ERCP:
-
Endoscopic retrograde cholangiopancreatography
- EUS:
-
Endoscopic ultrasound
- FISH:
-
Fluorescence in situ hybridization
- FNA:
-
Fine needle aspiration
- GP:
-
Glycoprotein
- HLA:
-
Human leukocyte antigen
- IBD:
-
Inflammatory bowel disease
- IDUS:
-
Intraductal ultrasound
- IPSG:
-
International PSC Study Group
- miRNA:
-
Micro-RNA
- MRI:
-
Magnetic resonance imaging
- NGS:
-
Next-generation sequencing
- NKG2D:
-
Natural killer cell receptor G2D
- OLT:
-
Orthotopic liver transplantation
- PDG-PET:
-
Fluorodexyglucose-positron emission tomography
- PSC:
-
Primary sclerosing cholangitis
- ROS:
-
Reactive oxygen species
- SC:
-
Sclerosing cholangitis
- TUDCA:
-
Tauroursodeoxycholic acid
- UC:
-
Ulcerative colitis
- UDCA:
-
Ursodeoxycholic acid
- US:
-
Ultrasound
References
Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M (2018) Primary sclerosing cholangitis. Lancet (London, England) 391(10139):2547–2559. https://doi.org/10.1016/s0140-6736(18)30300-3
Ehlken H, Schramm C (2013) Primary sclerosing cholangitis and cholangiocarcinoma: pathogenesis and modes of diagnostics. Digestive Diseases 31(1):118–125. https://doi.org/10.1159/000347206
Karlsen TH, Folseraas T, Thorburn D, Vesterhus M (2017) Primary sclerosing cholangitis – a comprehensive review. Journal of Hepatology 67(6):1298–1323. https://doi.org/10.1016/j.jhep.2017.07.022
Chapman MH, Webster GJ, Bannoo S, Johnson GJ, Wittmann J, Pereira SP (2012) Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. European journal of gastroenterology & hepatology 24(9):1051–1058. https://doi.org/10.1097/MEG.0b013e3283554bbf
Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR (2009) High lifetime risk of cancer in primary sclerosing cholangitis. Journal of Hepatology 50(1):158–164. https://doi.org/10.1016/j.jhep.2008.08.013
Conrad K, Roggenbuck D, Laass MW (2014) Diagnosis and classification of ulcerative colitis. Autoimmunity reviews 13(4-5):463–466. https://doi.org/10.1016/j.autrev.2014.01.028
Freeman E, Majeed A, Kemp W, Roberts SK (2018) Long-term outcomes of primary sclerosing cholangitis: an australian non-transplant tertiary hospital perspective. Internal Medicine Journal. https://doi.org/10.1111/imj.14041
Nakamura K, Ito T, Kotoh K, Ihara E, Ogino H, Iwasa T, Tanaka Y, Iboshi Y, Takayanagi R (2012) Hepatopancreatobiliary manifestations of inflammatory bowel disease. Clinical Journal of Gastroenterology 5(1):1–8. https://doi.org/10.1007/s12328-011-0282-1
Yimam KK, Bowlus CL (2014) Diagnosis and classification of primary sclerosing cholangitis. Autoimmunity Reviews 13(4-5):445–450. https://doi.org/10.1016/j.autrev.2014.01.040
Toy E, Balasubramanian S, Selmi C, Li CS, Bowlus CL (2011) The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. Bmc Gastroenterology 11. https://doi.org/10.1186/1471-230x-11-83
Lindor KD, Kowdley KV, Harrison ME (2015) ACG clinical guideline: primary sclerosing cholangitis. American Journal Of Gastroenterology 110(5):646–659. https://doi.org/10.1038/ajg.2015.112
Liang H, Manne S, Shick J, Lissoos T, Dolin P (2017) Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom. Medicine 96(24):e7116. https://doi.org/10.1080/17474124.2017.1343666,10.1097/md.0000000000007116
Weismuller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Farkkila MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouilleres O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM (2017) Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 152(8):1975–1984.e1978. https://doi.org/10.1053/j.gastro.2017.02.038
Bjornsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, Schrumpf E, Chapman RW (2002) Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 51(5):731–735. https://doi.org/10.1136/gut.51.5.731
Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, Boberg KM, Angulo P (2008) The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 134(4):975–980. https://doi.org/10.1053/j.gastro.2008.01.042
Broome U, Glaumann H, Lindstom E, Loof L, Almer S, Prytz H, Sandberg-Gertzen H, Lindgren S, Fork FT, Jarnerot G, Olsson R (2002) Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). Journal of hepatology 36(5):586–589
Singal AK, Stanca CM, Clark V, Dixon L, Levy C, Odin JA, Fiel MI, Friedman SL, Bach N (2011) Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. Hepatology international 5(3):808–813. https://doi.org/10.1007/s12072-011-9260-4
Aoki CA, Bowlus CL, Gershwin ME (2005) The immunobiology of primary sclerosing cholangitis. Autoimmunity Reviews 4(3):137–143. https://doi.org/10.1016/j.autrev.2004.09.003
Cullen S, Chapman R (2003) Primary sclerosing cholangitis. Autoimmunity Reviews 2(6):305–312
Ferri PM, Silva A, Silva SLC, de Aquino DJQ, Fagundes EDT, Demiranda DM, Ferreira AR (2016) The role of genetic and immune factors for the pathogenesis of primary sclerosing cholangitis in childhood. Gastroenterology Research And Practice. https://doi.org/10.1155/2016/3905240
Folseraas T, Liaskou E, Anderson CA, Karlsen TH (2015) Genetics in PSC: what do the “risk genes” teach us? Clinical Reviews in Allergy & Immunology 48(2-3):154–164. https://doi.org/10.1007/s12016-014-8417-z
O'Hara SP, Karlsen TH, LaRusso NF (2017) Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link? Gut 66 (11):1873-1877. doi:10.1016/j.bbadis.2017.07.038, https://doi.org/10.1136/gutjnl-2017-314249
Rojas M, Restrepo-Jimenez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramirez-Santana C, Leung PSC, Ansari AA, Gershwin ME, Anaya JM (2018) Molecular mimicry and autoimmunity. J Autoimmun 95:100–123. https://doi.org/10.1016/j.jaut.2018.10.012
Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BWM, Poen AC, van Nieuwkerk KM, Drenth JP, Witteman BJ, Tuynman HA, Naber AH, Kingma PJ, van Buuren HR, van Hoek B, Vleggaar FP, van Geloven N, Beuers U, Ponsioen CY, Epi PSG (2013) Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58(6):2045–2055. https://doi.org/10.1002/hep.26565
Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG (2011) Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 53(5):1590–1599. https://doi.org/10.1002/hep.24247
Tanaka A, Takikawa H (2013) Geoepidemiology of primary sclerosing cholangitis: a critical review. Journal Of Autoimmunity 46:35–40. https://doi.org/10.1016/j.jaut.2013.07.005
Tanaka A, Takamori Y, Toda G, Ohnishi S, Takikawa H (2008) Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver International: Official Journal of the International Association for the Study of the Liver 28(7):983–989. https://doi.org/10.1111/j.1478-3231.2008.01726.x
Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, SandbergGertzen H, Wallerstedt S, Lindberg G (1996) Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38(4):610–615. https://doi.org/10.1136/gut.38.4.610
Sogaard KK, Erichsen R, Lund JL, Farkas DK, Sorensen HT (2014) Cholangitis and subsequent gastrointestinal cancer risk: a Danish population-based cohort study. Gut 63(2):356–361. https://doi.org/10.1136/gutjnl-2013-305039
Takakura WR, Tabibian JH, Bowlus CL (2017) The evolution of natural history of primary sclerosing cholangitis. Current Opinion in Gastroenterology 33(2):71–77. https://doi.org/10.1097/mog.0000000000000333
Hrad V, Abebe Y, Ali SH, Velgersdyk J, Al Hallak M (2016) Risk and surveillance of cancers in primary biliary tract disease, vol 2016, p 3432640. https://doi.org/10.1155/2016/3432640
Bergquist A, von Seth E (2015) Epidemiology of cholangiocarcinoma. Best Practice & Research Clinical Gastroenterology 29(2):221–232. https://doi.org/10.1016/j.bpg.2015.02.003
Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD (2004) Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. American Journal Of Gastroenterology 99(3):523–526. https://doi.org/10.1111/j.1572-0241.2004.04067.x
de Vries EM, de Krijger M, Farkkila M, Arola J, Schirmacher P, Gotthardt D, Goeppert B, Trivedi PJ, Hirschfield GM, Ytting H, Vainer B, Buuren HR, Biermann K, Harms MH, Chazouilleres O, Wendum D, Kemgang AD, Chapman RW, Wang LM, Williamson KD, Gouw AS, Paradis V, Sempoux C, Beuers U, Hubscher SG, Verheij J, Ponsioen CY (2017) Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: an international cohort study. Hepatology 65(3):907–919. https://doi.org/10.1002/hep.28963
Fevery J, Henckaerts L, Van Oirbeek R, Vermeire S, Rutgeerts P, Nevens F, Van Steenbergen W (2012) Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study. Liver International 32(2):214–222. https://doi.org/10.1111/j.1478-3231.2011.02575.x
Liu K, Wang R, Kariyawasam V, Wells M, Strasser SI, McCaughan G, Corte C, Leong RW (2017) Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort. Liver International: Official Journal of the International Association for the Study of the Liver 37(3):442–448. https://doi.org/10.1111/liv.13328
de Valle MB, Bjornsson E, Lindkvist B (2012) Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver International 32(3):441–448. https://doi.org/10.1111/j.1478-3231.2011.02614.x
Ngu JH, Gearry RB, Frampton CM, Stedman CA (2012) Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 55(2):522–529. https://doi.org/10.1002/hep.24743
Timmer MR, Beuers U, Fockens P, Ponsioen CY, Rauws EA, Wang KK, Krishnadath KK (2013) Genetic and epigenetic abnormalities in primary sclerosing cholangitis-associated cholangiocarcinoma. Inflammatory Bowel Diseases 19(8):1789–1797. https://doi.org/10.1097/MIB.0b013e318281f49a
Ehlken H, Zenouzi R, Schramm C (2017) Risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: diagnosis and surveillance. Current Opinion In Gastroenterology 33(2):78–84. https://doi.org/10.1097/mog.0000000000000335
Morris-Stiff G, Bhati C, Olliff S, Hubscher S, Gunson B, Mayer D, Mirza D, Buckels J, Bramhall SR (2008) Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Digestive Surgery 25(2):126–132. https://doi.org/10.1159/000128169
Navaneethan U (2016) Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: finding a needle in a haystack. Endoscopy 48(5):417–418. https://doi.org/10.1055/s-0042-103420
Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, Reitsma JB, Heisterkamp SH, Tytgat GN (2002) Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 51(4):562–566
Ali AH, Tabibian JH (2018) Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology 67(6):2338-2351. https://doi.org/10.1002/hep.29730
Trilianos P, Selaru F, Li ZP, Gurakar A (2014) Trends in pre-liver transplant screening for cholangiocarcinoma among patients with primary sclerosing cholangitis. Digestion 89(2):165–173. https://doi.org/10.1159/000357445
Boyd S, Tenca A, Jokelainen K, Mustonen H, Krogerus L, Arola J, Färkkilä MA (2016) Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia. Endoscopy 48(5):432–439. https://doi.org/10.1055/s-0041-110792
Chung BK, Karlsen TH, Folseraas T (2017) Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma. Biochimica et biophysica acta. https://doi.org/10.1016/j.bbadis.2017.08.020
Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W (2007) Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Digestive Diseases And Sciences 52(11):3123–3135. https://doi.org/10.1007/s10620-006-9681-4
Thanan R, Pairojkul C, Pinlaor S, Khuntikeo N, Wongkham C, Sripa B, Ma N, Vaeteewoottacharn K, Furukawa A, Kobayashi H, Hiraku Y, Oikawa S, Kawanishi S, Yongvanit P, Murata M (2013) Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. Free Radical Biology & Medicine 65:1464–1472. https://doi.org/10.1016/j.freeradbiomed.2013.07.034
Finzi L, Shao MX, Paye F, Housset C, Nadel JA (2009) Lipopolysaccharide initiates a positive feedback of epidermal growth factor receptor signaling by prostaglandin E2 in human biliary carcinoma cells. Journal of immunology (Baltimore, Md : 1950) 182(4):2269–2276. https://doi.org/10.4049/jimmunol.0801768
Chabu C, Li DM, Xu T (2017) EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth. Nature communications 8:14688. https://doi.org/10.1038/ncomms14688
Lozano E, Sanchez-Vicente L, Monte MJ, Herraez E, Briz O, Banales JM, Marin JJ, Macias RI (2014) Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Molecular Cancer Research: MCR 12(1):91–100. https://doi.org/10.1158/1541-7786.mcr-13-0503
Boyd S, Mustonen H, Tenca A, Jokelainen K, Arola J, Farkkila MA (2017) Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma. Scandinavian Journal of Gastroenterology 52(2):242–249. https://doi.org/10.1080/00365521.2016.1250281
Eaton JE, Barr Fritcher EG, Gores GJ, Atkinson EJ, Tabibian JH, Topazian MD, Gossard AA, Halling KC, Kipp BR, Lazaridis KN (2015) Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis. The American Journal of Gastroenterology 110(2):299–309. https://doi.org/10.1038/ajg.2014.433
Kerr SE, Barr Fritcher EG, Campion MB, Voss JS, Kipp BR, Halling KC, Lewis JT (2014) Biliary dysplasia in primary sclerosing cholangitis harbors cytogenetic abnormalities similar to cholangiocarcinoma. Human Pathology 45(9):1797–1804. https://doi.org/10.1016/j.humpath.2014.05.008
Rizvi S, Eaton JE, Gores GJ (2015) Primary sclerosing cholangitis as a premalignant biliary tract disease: surveillance and management. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 13(12):2152–2165. https://doi.org/10.1016/j.cgh.2015.05.035
Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC (2010) Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. American Journal Of Surgical Pathology 34(1):27–34
Zarski JP, Barange K, Souvignet C, Bertini M, Marcellin P, Tran A, Deugnier Y, Couzigou P, Plages A, Ambroise-Thomas P (2001) Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. Journal of Hepatology 34(3):360–365. https://doi.org/10.1016/S0168-8278(00)00034-9
Boyd S, Vannas M, Jokelainen K, Isoniemi H, Mäkisalo H, Färkkilä MA, Arola J (2017) Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis. World Journal of Gastroenterology 23(33):6147–6154. https://doi.org/10.3748/wjg.v23.i33.6147
Carpino G, Cardinale V, Folseraas T, Overi D, Grzyb K, Costantini D, Berloco PB, Di Matteo S, Karlsen TH, Alvaro D, Gaudio E (2018) Neoplastic transformation of peribiliary stem cell niche in cholangiocarcinoma arisen in primary sclerosing cholangitis. Hepatology. https://doi.org/10.1016/j.gtc.2018.04.007,10.1002/hep.30210
Ahrendt SA, Eisenberger CF, Yip L, Rashid A, Chow JT, Pitt HA, Sidransky D (1999) Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. The Journal of surgical research 84(1):88–93. https://doi.org/10.1006/jsre.1999.5615
Ahrendt SA, Rashid A, Chow JT, Eisenberger CF, Pitt HA, Sidransky D (2000) p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. Journal of hepato-biliary-pancreatic surgery 7(4):426–431. https://doi.org/10.1007/s005340050212
Boberg KM, Schrumpf E, Bergquist A, Broome U, Pares A, Remotti H, Schjolberg A, Spurkland A, Clausen OP (2000) Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol 32(3):374–380
Taniai M, Higuchi H, Burgart LJ, Gores GJ (2002) p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 123(4):1090–1098
Timmer MR, Lau CT, Meijer SL, Fockens P, Rauws EA, Ponsioen CY, Calpe S, Krishnadath KK (2016) Genetic abnormalities in biliary brush samples for distinguishing cholangiocarcinoma from benign strictures in primary sclerosing cholangitis. Gastroenterol Res Pract 2016:4381513. https://doi.org/10.1155/2016/4381513
Jinesh GG, Sambandam V, Vijayaraghavan S, Balaji K, Mukherjee S (2017) Molecular genetics and cellular events of K-Ras-driven tumorigenesis. Oncogene. https://doi.org/10.1038/onc.2017.377
Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Bottcher K, Folseraas T, Weismuller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Bjorkstrom NK, Beuers U, Bjornsson E, Boberg KM, Bowlus CL, Bragazzi MC, Carbone M, Chazouilleres O, Cheung A, Dalekos G, Eaton J, Eksteen B, Ellinghaus D, Farkkila M, Festen EAM, Floreani A, Franceschet I, Gotthardt DN, Hirschfield GM, Hoek BV, Holm K, Hohenester S, Hov JR, Imhann F, Invernizzi P, Juran BD, Lenzen H, Lieb W, Liu JZ, Marschall HU, Marzioni M, Melum E, Milkiewicz P, Muller T, Pares A, Rupp C, Rust C, Sandford RN, Schramm C, Schreiber S, Schrumpf E, Silverberg MS, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila AV, Vries B, Zachou K, Chapman RW, Manns MP, Pinzani M, Rushbrook SM, Lazaridis KN, Franke A, Anderson CA, Karlsen TH, Ponsioen CY, Weersma RK (2018) Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut 67(8):1517–1524. https://doi.org/10.1136/gutjnl-2016-313598
Cheung AC, LaRusso NF, Gores GJ, Lazaridis KN (2017) Epigenetics in the primary biliary cholangitis and primary sclerosing cholangitis. Seminars in liver disease 37(2):159–174. https://doi.org/10.1055/s-0037-1603324
Melum E, Franke A, Schramm C, Weismuller TJ, Gotthardt DN, Offner FA, Juran BD, Laerdahl JK, Labi V, Bjornsson E, Weersma RK, Henckaerts L, Teufel A, Rust C, Ellinghaus E, Balschun T, Boberg KM, Ellinghaus D, Bergquist A, Sauer P, Ryu E, Hov JR, Wedemeyer J, Lindkvist B, Wittig M, Porte RJ, Holm K, Gieger C, Wichmann HE, Stokkers P, Ponsioen CY, Runz H, Stiehl A, Wijmenga C, Sterneck M, Vermeire S, Beuers U, Villunger A, Schrumpf E, Lazaridis KN, Manns MP, Schreiber S, Karlsen TH (2011) Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nature genetics 43(1):17–19. https://doi.org/10.1038/ng.728
Melum E, Karlsen TH, Schrumpf E, Bergquist A, Thorsby E, Boberg KM, Lie BA (2008) Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 47(1):90–96. https://doi.org/10.1002/hep.21964
Paziewska A, Habior A, Rogowska A, Zych W, Goryca K, Karczmarski J, Dabrowska M, Ambrozkiewicz F, Walewska-Zielecka B, Krawczyk M, Cichoz-Lach H, Milkiewicz P, Kowalik A, Mucha K, Raczynska J, Musialik J, Boryczka G, Wasilewicz M, Ciecko-Michalska I, Ferenc M, Janiak M, Kanikowska A, Stankiewicz R, Hartleb M, Mach T, Grzymislawski M, Raszeja-Wyszomirska J, Wunsch E, Bobinski T, Mikula M, Ostrowski J (2017) A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients. BMC medical genomics 10(1):2. https://doi.org/10.1186/s12920-016-0239-9
Wiencke K, Louka AS, Spurkland A, Vatn M, Schrumpf E, Boberg KM (2004) Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients. Journal of hepatology 41(2):209–214. https://doi.org/10.1016/j.jhep.2004.04.024
Voigtlander T, Gupta SK, Thum S, Fendrich J, Manns MP, Lankisch TO, Thum T (2015) MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma. PloS one 10(10):e0139305. https://doi.org/10.1371/journal.pone.0139305
Bernuzzi F, Marabita F, Lleo A, Carbone M, Mirolo M, Marzioni M, Alpini G, Alvaro D, Boberg KM, Locati M, Torzilli G, Rimassa L, Piscaglia F, He XS, Bowlus CL, Yang GX, Gershwin ME, Invernizzi P (2016) Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clinical and Experimental Immunology 185(1):61–71. https://doi.org/10.1111/cei.12776
Loosen SH, Lurje G, Wiltberger G, Vucur M, Koch A, Kather JN, Paffenholz P, Tacke F, Ulmer FT, Trautwein C, Luedde T, Neumann UP, Roderburg C (2019) Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma. PLOs One 14(1):e0210944. https://doi.org/10.1371/journal.pone.0210944
Wu X, Xia M, Chen D, Wu F, Lv Z, Zhan Q, Jiao Y, Wang W, Chen G, An F (2016) Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 37(11):15019–15029. https://doi.org/10.1007/s13277-016-5313-6
Koutsaki M, Spandidos DA, Zaravinos A (2014) Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics. Cancer letters 351(2):173–181. https://doi.org/10.1016/j.canlet.2014.05.022
Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzen H, Almer S, Granath F, Broome U (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. Journal of hepatology 36(3):321–327
Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broome U, Chapman R, Fausa O, Egeland T, Rocca G, Schrumpf E (2002) Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scandinavian Journal of Gastroenterology 37(10):1205–1211
Saadi M, Yu C, Othman MO (2014) A review of the challenges associated with the diagnosis and therapy of primary sclerosing cholangitis. Journal of Clinical and Translational Hepatology 2(1):45–52. https://doi.org/10.14218/jcth.2013.00021
Bonato G, Cristoferi L, Strazzabosco M, Fabris L (2015) Malignancies in primary sclerosing cholangitis - a continuing threat. Digestive diseases (Basel, Switzerland) 33 Suppl 2:140-148. https://doi.org/10.1159/000440826
Ponsioen CY (2015) Diagnosis, differential diagnosis, and epidemiology of primary sclerosing cholangitis. Digestive Diseases 33:134–139. https://doi.org/10.1159/000440823
Geramizadeh B, Ghavvas R, Kazemi K, Shamsaeefar A, Nikeghbalian S, Malekhosseini SA (2015) Cholangiocarcinoma secondary to primary sclerosing cholangitis in explanted livers: a single-center study in the South of Iran. Hepatitis Monthly 15(12):e33626. https://doi.org/10.5812/hepatmon.33626
Mouchli MA, Singh S, Loftus EV, Boardman L, Talwalkar J, Rosen CB, Heimbach JK, Wiesner RH, Hasan B, Poterucha JJ, Watt KD (2017) Risk factors and outcomes of de novo cancers (excluding nonmelanoma skin cancer) after liver transplantation for primary sclerosing cholangitis. Transplantation. https://doi.org/10.1097/TP.0000000000001725
Rademacher S, Seehofer D, Eurich D, Schoening W, Neuhaus R, Oellinger R, Denecke T, Pascher A, Schott E, Sinn M, Neuhaus P, Pratschke J (2017) The 28-year incidence of de novo malignancies after liver transplantation: a single-center analysis of risk factors and mortality in 1616 patients. Liver Transplantation 23(11):1404–1414. https://doi.org/10.1002/lt.24795
Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B, Schrumpf E, Oksanen A, Ericzon BG, Hockerstedt K, Makisalo H, Kirkegaard P, Friman S, Bjoro K (2004) Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. Journal of hepatology 40(5):815–822. https://doi.org/10.1016/j.jhep.2004.01.002
Rudolph G, Gotthardt D, Kloters-Plachky P, Kulaksiz H, Rost D, Stiehl A (2009) Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. Journal of hepatology 51(1):149–155. https://doi.org/10.1016/j.jhep.2009.01.023
Aabakken L, Karlsen TH, Albert J, Arvanitakis M, Chazouilleres O, Dumonceau JM, Farkkila M, Fickert P, Hirschfield GM, Laghi A, Marzioni M, Fernandez M, Pereira SP, Pohl J, Poley JW, Ponsioen CY, Schramm C, Swahn F, Tringali A, Hassan C (2017) Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy 49(6):588–608. https://doi.org/10.1111/liv.13276,10.1055/s-0043-107029
Taghavi SA, Eshraghian A, Niknam R, Sivandzadeh GR, Bagheri Lankarani K (2018) Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Expert Review Gastroenterology Hepatology 12(6):575-584. https://doi.org/10.1080/17474124.2018.1473761
Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD (2008) Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 48(4):1106–1117. https://doi.org/10.1002/hep.22441
Manninen P, Karvonen AL, Laukkarinen J, Aitola P, Huhtala H, Collin P (2015) Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease. Scandinavian Journal Of Gastroenterology 50(4):423–428. https://doi.org/10.3109/00365521.2014.946085
Rizvi S, Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145(6):1215–1229. https://doi.org/10.1053/j.gastro.2013.10.013
Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD (2011) Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 9 (5):434-439.e431. doi:https://doi.org/10.1016/j.cgh.2011.02.007
Fevery J, Verslype C (2010) An update on cholangiocarcinoma associated with primary sclerosing cholangitis. Current Opinion In Gastroenterology 26(3):236–245. https://doi.org/10.1097/MOG.0b013e328337b311
Trilianos P, Agnihotri A, Ucbilek E, Gurakar A (2016) Greater biosynthetic liver dysfunction in primary sclerosing cholangitis suggests co-existent or impending cholangiocarcinoma. Journal of Clinical and Translational Hepatology 4(1):1–4. https://doi.org/10.14218/jcth.2015.00048
Rosen CB, Heimbach JK, Gores GJ (2010) Liver transplantation for cholangiocarcinoma. Transplant International: Official Journal of the European Society for Organ Transplantation 23(7):692–697. https://doi.org/10.1111/j.1432-2277.2010.01108.x
Jendrek ST, Gotthardt D, Nitzsche T, Widmann L, Korf T, Michaels MA, Weiss KH, Liaskou E, Vesterhus M, Karlsen TH, Mindorf S, Schemmer P, Bar F, Teegen B, Schroeder T, Ehlers M, Hammers CM, Komorowski L, Lehnert H, Fellermann K, Derer S, Hov JR, Sina C (2017) Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut 66(1):137–144
Garioud A, Seksik P, Chrétien Y, Corphechot C, Poupon R, Poupon RE, Chazouillères O (2010) Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. European Journal of Gastroenterology and Hepatology 22(7):842–847. https://doi.org/10.1097/MEG.0b013e328331c2b7
Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A (2007) The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. European Journal Of Gastroenterology & Hepatology 19(6):487–491. https://doi.org/10.1097/MEG.0b013e3281108068
Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WMC, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61(12):1657–1669. https://doi.org/10.1136/gutjnl-2011-301748
Olsson R, Boberg KM, De Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsoy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzen H, Ung KA, Eriksson A, Loof L, Prytz H, Marschall HL, Broome U (2005) High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129(5):1464–1472. https://doi.org/10.1053/j.gastro.2005.08.017
Othman MO, Dunkelberg J, Roy PK (2012) Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review. Arab Journal of Gastroenterology: The Official Publication of the Pan-Arab Association of Gastroenterology 13(3):103–110. https://doi.org/10.1016/j.ajg.2012.06.011
Saffioti F, Gurusamy KS, Hawkins N, Toon CD, Tsochatzis E, Davidson BR, Thorburn D (2017) Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. The Cochrane database of systematic reviews 3:Cd011343. https://doi.org/10.1002/14651858.CD011343.pub2
Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK (2011) Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Alimentary Pharmacology & Therapeutics 34(8):901–910. https://doi.org/10.1111/j.1365-2036.2011.04822.x
Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN (2007) Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. The American Journal of Gastroenterology 102(1):107–114. https://doi.org/10.1111/j.1572-0241.2006.00872.x
Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J (2016) Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology 64(4):1178–1188. https://doi.org/10.1002/hep.28744
Stremitzer S, Jones RP, Quinn LM, Fenwick SW, Diaz-Nieto R, Poston GJ, Malik HZ (2018) Clinical outcome after resection of early-stage hilar cholangiocarcinoma. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 45:213–217. https://doi.org/10.1016/j.ejso.2018.09.008
Chung BK, Guevel BT, Reynolds GM, Gupta Udatha DB, Henriksen EK, Stamataki Z, Hirschfield GM, Karlsen TH, Liaskou E (2017) Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis. Journal of Autoimmunity 77:45–54. https://doi.org/10.1016/j.jaut.2016.10.003
Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D (2018) The clinical usage and definition of autoantibodies in immune-mediated liver disease: a comprehensive overview. J Autoimmun 95:144–158. https://doi.org/10.1016/j.jaut.2018.10.004
Banales JM, Inarrairaegui M, Arbelaiz A, Milkiewicz P, Muntane J, Munoz-Bellvis L, La Casta A, Gonzalez LM, Arretxe E, Alonso C, Martinez-Arranz I, Lapitz A, Santos-Laso A, Avila MA, Martinez-Chantar ML, Bujanda L, Marin JJG, Sangro B, Macias RIR (2018) Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis. https://doi.org/10.1002/hep.30319
Kuzu UB, Odemis B, Suna N, Yildiz H, Parlak E, Disibeyaz S, Torun S, Akpinar MY, Coskun O, Turhan N, Yuksel M, Kayacetin E (2016) The detection of cholangiocarcinoma in primary sclerosing cholangitis patients: single center experience. Journal of Gastrointestinal Cancer 47(1):8–14. https://doi.org/10.1007/s12029-015-9777-1
Lee JJ, Schindera ST, Jang HJ, Fung S, Kim TK (2017) Cholangiocarcinoma and its mimickers in primary sclerosing cholangitis. Abdominal Radiology 42(12):2898-2908. 10.3748/wjg.v23.i33.6147, 10.1007/s00261-017-1328-8
Wannhoff A, Gotthardt DN (2018) Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis. Clinics and Research in Hepatology and Gastroenterology. https://doi.org/10.1016/j.clinre.2018.08.013
Wannhoff A, Hov JR, Folseraas T, Rupp C, Friedrich K, Anmarkrud JA, Weiss KH, Sauer P, Schirmacher P, Boberg KM, Stremmel W, Karlsen TH, Gotthardt DN (2013) FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. Journal of Hepatology 59(6):1278–1284. https://doi.org/10.1016/j.jhep.2013.08.005
Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD (2005) The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Digestive Diseases and Sciences 50(9):1734–1740. https://doi.org/10.1007/s10620-005-2927-8
Liu W, Liu Q, Wang W, Wang P, Chen J, Hong T, Zhang N, Li B, Qu Q, He X (2018) Differential diagnostic roles of the serum CA19-9, total bilirubin (TBIL) and the ratio of CA19-9 to TBIL for benign and malignant. Journal of Cancer 9(10):1804–1812. https://doi.org/10.7150/jca.25093
Wannhoff A, Rupp C, Friedrich K, Knierim J, Flechtenmacher C, Weiss KH, Stremmel W, Gotthardt DN (2017) Carcinoembryonic antigen level in primary sclerosing cholangitis is not influenced by dominant strictures or bacterial cholangitis. Dig Dis Sci 62(2):510–516. https://doi.org/10.4037/aacnacc2016202,10.1007/s10620-016-4370-4
Nasser-Ghodsi N, Lennon RJ, DeLeon T, Borad MJ, Hilscher M, Silveira MG, Carey EJ, Lindor KD, Loosen SH (2017) CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. Hepatology 7(1):16975. https://doi.org/10.1002/hep.29730,10.1038/s41598-017-17175-7
Wannhoff A, Folseraas T, Brune M, Rupp C, Friedrich K, Knierim J, Weiss KH, Sauer P, Flechtenmacher C, Schirmacher P, Stremmel W, Hov JR, Gotthardt DN (2016) A common genetic variant of fucosyltransferase 2 correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis. United European Gastroenterology Journal 4(1):84–91. https://doi.org/10.1177/2050640615581577
Sowa M, Kolenda R, Baumgart DC, Pratschke J, Papp M, Tornai T, Suchanski J, Bogdanos DP, Mytilinaiou MG, Hammermann J, Laass MW, Conrad K, Schramm C, Franke A, Roggenbuck D, Schierack P (2018) Mucosal autoimmunity to cell-bound GP2 isoforms is a sensitive marker in PSC and associated with the clinical phenotype. Frontiers in Immunology 9:1959. https://doi.org/10.3389/fimmu.2018.01959
Cuenco J, Wehnert N, Blyuss O, Kazarian A, Whitwell HJ, Menon U, Dawnay A, Manns MP, Pereira SP, Timms JF (2018) Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis. Oncotarget 9(25):17430–17442. https://doi.org/10.1016/j.gtc.2018.01.002,10.18632/oncotarget.24732
Rizvi S, Eaton J, Yang JD, Chandrasekhara V, Gores GJ (2018) Emerging technologies for the diagnosis of perihilar cholangiocarcinoma. Seminars in Liver Disease 38(2):160–169. https://doi.org/10.1055/s-0038-1655775
Albiin N, Smith IC, Arnelo U, Lindberg B, Bergquist A, Dolenko B, Bryksina N, Bezabeh T (2008) Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiologica (Stockholm, Sweden : 1987) 49(8):855–862. https://doi.org/10.1080/02841850802220092
Lankisch TO, Metzger J, Negm AA, Vosskuhl K, Schiffer E, Siwy J, Weismuller TJ, Schneider AS, Thedieck K, Baumeister R, Zurbig P, Weissinger EM, Manns MP, Mischak H, Wedemeyer J (2011) Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 53(3):875–884. https://doi.org/10.1002/hep.24103
Metzger J, Negm AA, Plentz RR, Weismüller TJ, Wedemeyer J, Karlsen TH, Dakna M, Mullen W, Mischak H, Manns MP, Lankisch TO (2013) Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 62(1):122–130. https://doi.org/10.1136/gutjnl-2012-302047
Voigtlander T, Metzger J, Schonemeier B, Jager M, Mischak H, Manns MP, Lankisch TO (2017) A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin. United European gastroenterology journal 5(5):668–676. https://doi.org/10.1177/2050640616687836
Dudley JC, Zheng Z, McDonald T, Le LP, Dias-Santagata D, Borger D, Batten J, Vernovsky K, Sweeney B, Arpin RN, Brugge WR, Forcione DG, Pitman MB, Iafrate AJ (2016) Next-Generation sequencing and fluorescence in situ hybridization have comparable performance characteristics in the analysis of pancreaticobiliary brushings for malignancy. The Journal of molecular diagnostics : JMD 18(1):124–130. https://doi.org/10.1016/j.jmoldx.2015.08.002
Schramm C, Eaton J, Ringe KI, Venkatesh S, Yamamura J (2017) Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology 66(5):1675–1688. https://doi.org/10.1002/hep.29293
Ma KW, Cheung TT, She WH, Chok KSH, Chan ACY, Dai WC, Chiu WH, Lo CM (2018) Diagnostic and prognostic role of 18-FDG PET/CT in the management of resectable biliary tract cancer. World Journal of Surgery 42(3):823–834. https://doi.org/10.1007/s00268-017-4192-3
Sangfelt P, Sundin A, Wanders A, Rasmussen I, Karlson BM, Bergquist A, Rorsman F (2014) Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET. Journal of Hepatology 61(6):1352–1357. https://doi.org/10.1016/j.jhep.2014.07.032
Alkhawaldeh K, Faltten S, Biersack HJ, Ezziddin S (2011) The value of F-18 FDG PET in patients with primary sclerosing cholangitis and cholangiocarcinoma using visual and semiquantitative analysis. Clinical Nuclear Medicine 36(10):879–883. https://doi.org/10.1097/RLU.0b013e3182291a64
Fevery J, Buchel O, Nevens F, Verslype C, Stroobants S, Van Steenbergen W (2005) Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Journal of Hepatology 43(2):358–360. https://doi.org/10.1016/j.jhep.2005.03.016
Horsley-Silva JL, Rodriguez EA, Franco DL, Lindor KD (2017) An update on cancer risk and surveillance in primary sclerosing cholangitis. Liver International 37(8):1103-1109. doi:https://doi.org/10.1111/liv.13354
Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA (2015) Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointestinal Endoscopy 81(1):168–176. https://doi.org/10.1016/j.gie.2014.09.017
Trikudanathan G, Navaneethan U, Njei B, Vargo JJ, Parsi MA (2014) Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointestinal Endoscopy 79(5):783–789. https://doi.org/10.1016/j.gie.2013.09.015
Vannas MJ, Boyd S, Farkkila MA, Arola J, Isoniemi H (2017) Value of brush cytology for optimal timing of liver transplantation in primary sclerosing cholangitis. Liver International : Official Journal of the International Association for the Study of the Liver 37(5):735–742. https://doi.org/10.3748/wjg.v23.i14.2459,10.1111/liv.13276
Barr Fritcher EG, Voss JS, Jenkins SM, Lingineni RK, Clayton AC, Roberts LR, Halling KC, Talwalkar JA, Gores GJ, Kipp BR (2013) Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. Cancer cytopathology 121(12):708–717. https://doi.org/10.1002/cncy.21331
Nanda A, Brown JM, Berger SH, Lewis MM, Barr Fritcher EG, Gores GJ, Keilin SA, Woods KE, Cai Q, Willingham FF (2015) Triple modality testing by endoscopic retrograde cholangiopancreatography for the diagnosis of cholangiocarcinoma. Therapeutic advances in gastroenterology 8(2):56–65. https://doi.org/10.1177/1756283x14564674
Bangarulingam SY, Bjornsson E, Enders F, Barr Fritcher EG, Gores G, Halling KC, Lindor KD (2010) Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 51(1):174–180. https://doi.org/10.1002/hep.23277
Navaneethan U, Njei B, Venkatesh PG, Vargo JJ, Parsi MA (2014) Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastroenterol Endosc 79(6):943–950.e943. https://doi.org/10.1016/j.gie.2013.11.001
Njei B, McCarty TR, Varadarajulu S, Navaneethan U (2016) Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Alimentary Pharmacology & Therapeutics 44(11-12):1139–1151. https://doi.org/10.1111/apt.13817
Barr Fritcher EG, Kipp BR, Voss JS, Clayton AC, Lindor KD, Halling KC, Gores GJ (2011) Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. The American Journal of Gastroenterology 106(11):2023–2028. https://doi.org/10.1038/ajg.2011.272
Quinn KP, Tabibian JH, Lindor KD (2017) Clinical implications of serial versus isolated biliary fluorescence in situ hybridization (FISH) polysomy in primary sclerosing cholangitis. Scand J Gastroenterol 52(4):377–381. https://doi.org/10.1016/j.bpg.2016.11.001,10.1080/00365521.2016.1263681
Liew ZH, Loh TJ, Lim TKH, Lim TH, Khor CJL, Mesenas SJ, Kong CSC, Ong WC, Tan DMY (2018) Role of fluorescence in situ hybridization in diagnosing cholangiocarcinoma in indeterminate biliary strictures. Journal of Gastroenterology And Hepatology 33(1):315–319. https://doi.org/10.1002/hep.29291,10.1111/jgh.13824
Levy MJ, Baron TH, Clayton AC, Enders FB, Gostout CJ, Halling KC, Kipp BR, Petersen BT, Roberts LR, Rumalla A, Sebo TJ, Topazian MD, Wiersema MJ, Gores GJ (2008) Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. The American Journal of Gastroenterology 103(5):1263–1273. https://doi.org/10.1111/j.1572-0241.2007.01776.x
Moreno Luna LE, Kipp B, Halling KC, Sebo TJ, Kremers WK, Roberts LR, Barr Fritcher EG, Levy MJ, Gores GJ (2006) Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 131(4):1064–1072. https://doi.org/10.1053/j.gastro.2006.08.021
Barr Fritcher EG, Voss JS, Brankley SM, Campion MB, Jenkins SM, Keeney ME, Henry MR, Kerr SM, Chaiteerakij R, Pestova EV, Clayton AC, Zhang J, Roberts LR, Gores GJ, Halling KC, Kipp BR (2015) An optimized set of fluorescence in situ hybridization probes for detection of pancreatobiliary tract cancer in cytology brush samples. Gastroenterology 149(7):1813–1824.e1811. https://doi.org/10.1053/j.gastro.2015.08.046
Navaneethan U, Hasan MK, Kommaraju K, Zhu X, Hebert-Magee S, Hawes RH, Vargo JJ, Varadarajulu S, Parsi MA (2016) Digital, single-operator cholangiopancreatoscopy in the diagnosis and management of pancreatobiliary disorders: a multicenter clinical experience (with video). Gastrointestinal Endoscopy 84(4):649–655. https://doi.org/10.1016/j.gie.2016.03.789
Navaneethan U, Hasan MK, Lourdusamy V, Njei B, Varadarajulu S, Hawes RH (2015) Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. Gastrointestinal Endoscopy 82(4):608–614.e602. https://doi.org/10.1016/j.gie.2015.04.030
Siiki A, Rinta-Kiikka I, Koivisto T, Vasama K, Sand J, Laukkarinen J (2014) Spyglass single-operator peroral cholangioscopy seems promising in the evaluation of primary sclerosing cholangitis-related biliary strictures. Scandinavian Journal of Gastroenterology 49(11):1385–1390. https://doi.org/10.3109/00365521.2014.940376
Brooks C, Gausman V, Kokoy-Mondragon C, Munot K, Amin SP, Desai A, Kipp C, Poneros J, Sethi A, Gress FG, Kahaleh M, Murty VV, Sharaiha R, Gonda TA (2018) Role of fluorescent in situ hybridization, cholangioscopic biopsies, and EUS-FNA in the evaluation of biliary strictures. Digestive Diseases and Sciences 63(3):636–644. https://doi.org/10.1007/s10620-018-4906-x
Navaneethan U, Njei B, Venkatesh PG, Lourdusamy V, Sanaka MR (2015) Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis. Gastroenterology Report 3(3):209–215. https://doi.org/10.1093/gastro/gou057
Tellez-Avila FI, Bernal-Mendez AR, Guerrero-Vazquez CG, Martinez-Lozano JA, Ramirez-Luna MA (2014) Diagnostic yield of EUS-guided tissue acquisition as a first-line approach in patients with suspected hilar cholangiocarcinoma. The American Journal of Gastroenterology 109(8):1294–1296. https://doi.org/10.1038/ajg.2014.169
Gleeson FC, Rajan E, Levy MJ, Clain JE, Topazian MD, Harewood GC, Papachristou GI, Takahashi N, Rosen CB, Gores GJ (2008) EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointestinal Endoscopy 67(3):438–443. https://doi.org/10.1016/j.gie.2007.07.018
Heimbach JK, Sanchez W, Rosen CB, Gores GJ (2011) Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB: The Official Journal of the International Hepato Pancreato Biliary Association 13(5):356–360. https://doi.org/10.1111/j.1477-2574.2011.00298.x
Levy MJ, Heimbach JK, Gores GJ (2012) Endoscopic ultrasound staging of cholangiocarcinoma. Current Opinion in Gastroenterology 28(3):244–252. https://doi.org/10.1097/MOG.0b013e32835005bc
Slivka A, Gan I, Jamidar P, Costamagna G, Cesaro P, Giovannini M, Caillol F, Kahaleh M (2015) Validation of the diagnostic accuracy of probe-based confocal laser endomicroscopy for the characterization of indeterminate biliary strictures: results of a prospective multicenter international study. Gastrointestinal Endoscopy 81(2):282–290. https://doi.org/10.1016/j.gie.2014.10.009
Meister T, Heinzow HS, Woestmeyer C, Lenz P, Menzel J, Kucharzik T, Domschke W, Domagk D (2013) Intraductal ultrasound substantiates diagnostics of bile duct strictures of uncertain etiology. World Journal of Gastroenterology 19(6):874–881. https://doi.org/10.3748/wjg.v19.i6.874
Majeed A, Castedal M, Arnelo U, Soderdahl G, Bergquist A, Said K (2018) Optimizing the detection of biliary dysplasia in primary sclerosing cholangitis before liver transplantation. Scandinavian Journal of Gastroenterology 53(1):56–63. https://doi.org/10.5604/01.3001.0010.5273,10.1080/00365521.2017.1385840
Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL (2013) Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in utah children: epidemiology and natural history. Hepatology 58(4):1392–1400. https://doi.org/10.1002/hep.26454
Deneau MR, El-Matary W, Valentino PL, Abdou R, Alqoaer K, Amin M, Amir AZ, Auth M, Bazerbachi F, Broderick A, Chan A, Cotter J, Doan S, El-Youssef M, Ferrari F, Furuya KN, Gottrand M, Gottrand F, Gupta N, Homan M, Kamath BM, Kim KM, Kolho KL, Konidari A, Koot B, Iorio R, Ledder O, Mack C, Martinez M, Miloh T, Mohan P, O'Cathain N, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Smolka V, Tanaka A, Varier R, Venkat V, Vitola B, Vos MB, Woynarowski M, Yap J, Jensen MK (2017) The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration. Hepatology 66(2):518–527. https://doi.org/10.1002/hep.29204
Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010) Diagnosis and management of primary sclerosing cholangitis. Hepatology 51(2):660–678. https://doi.org/10.1002/hep.23294
Tischendorf JJ, Meier PN, Strassburg CP, Klempnauer J, Hecker H, Manns MP, Kruger M (2006) Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology 41(10):1227–1234. https://doi.org/10.1080/00365520600633495
Navaneethan U, Singh T, Gutierrez NG, Jegadeesan R, Venkatesh PG, Brainard J, Vargo JJ, Parsi MA (2014) Predictors for detection of cancer in patients with indeterminate biliary stricture and atypical cells on endoscopic retrograde brush cytology. Journal of Digestive Diseases 15(5):268–275. https://doi.org/10.1111/1751-2980.12134
Zhou Z, Nie SD, Jiang B, Wang J, Lv P (2018) Risk factors for extrahepatic cholangiocarcinoma: a case-control study in China. European Journal of Cancer Prevention: The Official Journal of the European Cancer Prevention Organisation (ECP). https://doi.org/10.1097/cej.0000000000000468
Gulamhusein AF, Eaton JE, Tabibian JH, Atkinson EJ, Juran BD, Lazaridis KN (2016) Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD. American Journal of Gastroenterology 111(5):705–711. https://doi.org/10.1038/ajg.2016.55
Horsley-Silva JL, Carey EJ, Lindor KD (2016) Advances in primary sclerosing cholangitis. The Lancet Gastroenterology & Hepatology 1(1):68–77. https://doi.org/10.1016/s2468-1253(16)30010-3
Ngu JH, Gearry RB, Wright AJ, Stedman CAM (2011) Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clinical Gastroenterology and Hepatology 9(12):1092–1097. https://doi.org/10.1016/j.cgh.2011.08.027
Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz SH (2017) Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut and liver. https://doi.org/10.5009/gnl16510
Rudolph G, Gotthardt D, Kloeters-Plachky P, Rost D, Kulaksiz H, Stiehl A (2010) In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. Journal Of Hepatology 53(2):313–317
Franceschet I, Cazzagon N, Del Ross T, D'Incà R, Buja A, Floreani A (2016) Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options. European Journal of Gastroenterology and Hepatology 28(5):508–513. https://doi.org/10.1097/MEG.0000000000000596
Fevery J, Van Steenbergen W, Van Pelt J, Laleman W, Hoffman I, Geboes K, Vermeire S, Nevens F (2016) Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD. Alimentary Pharmacology & Therapeutics 43(5):612–620. https://doi.org/10.1111/apt.13516
Halliday JS, Djordjevic J, Lust M, Culver EL, Braden B, Travis SP, Chapman RW (2012) A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. Journal of Crohn's & Colitis 6(2):174–181. https://doi.org/10.1016/j.crohns.2011.07.015
Plentz RR, Malek NP (2015) Clinical presentation, risk factors and staging systems of cholangiocarcinoma. Best Practice & Research Clinical Gastroenterology 29(2):245–252. https://doi.org/10.1016/j.bpg.2015.02.001
Zhou HB, Hu JY, Hu HP (2014) Hepatitis B virus infection and intrahepatic cholangiocarcinoma. World Journal Of Gastroenterology 20(19):5721–5729. https://doi.org/10.3748/wjg.v20.i19.5721
Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, Chari S, Lindor KD (2006) Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. The American Journal Of Gastroenterology 101(9):2070–2075. https://doi.org/10.1111/j.1572-0241.2006.00772.x
Zen Y, Harada K, Sasaki M, Sato Y, Tsuneyama K, Haratake J, Kurumaya H, Katayanagi K, Masuda S, Niwa H, Morimoto H, Miwa A, Uchiyama A, Portmann BC, Nakanuma Y (2004) IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis? The American Journal Of Surgical Pathology 28(9):1193–1203
Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, Topazian MD, Clain JE, Pearson RK, Petersen BT, Vege SS, Lindor K, Farnell MB (2008) Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134(3):706–715. https://doi.org/10.1053/j.gastro.2007.12.009
Rimassa L, Personeni N, Aghemo A, Lleo A (2019) The immune milieu of cholangiocarcinoma: from molecular pathogenesis to precision medicine. J Autoimmun 100:17–26. https://doi.org/10.1016/j.jaut.2019.03.007
Xie YQ, Ma HD, Lian ZX (2016) Epigenetics and primary biliary cirrhosis: a comprehensive review and implications for autoimmunity. Clinical Reviews in Allergy & Immunology 50(3):390–403. https://doi.org/10.1007/s12016-015-8502-y
Shu Y, Hu Q, Long H, Chang C, Lu Q, Xiao R (2017) Epigenetic variability of CD4+CD25+ tregs contributes to the pathogenesis of autoimmune diseases. Clinical Reviews in Allergy & Immunology 52(2):260–272. https://doi.org/10.1007/s12016-016-8590-3
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Song, J., Li, Y., Bowlus, C.L. et al. Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. Clinic Rev Allerg Immunol 58, 134–149 (2020). https://doi.org/10.1007/s12016-019-08764-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-019-08764-7